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Objectives: Newborn screening (NBS) for cystic ﬁbrosis (CF) began in Merseyside
and Cheshire in 2007. The UK protocol is IRT-DNA-IRT with a cut-off of 99.5%
for IRT-1. The DNA panel covers the 4 commonest UK mutations. For infants with
1 mutation a second IRT is measured at day 21 of life. In addition, infants with no
mutations but an IRT-1 >99.9th centile also have IRT-2 at day 21. There is interest
in the impact of these unique aspects of the UK protocol, and we have reviewed
our results to assess the sensitivity of the programme.
Methods: We reviewed the performance of the NBS programme in our UK region
matching data from the one screening laboratory with clinical data from the network.
Conclusion: 172,989 infants have been screened in our region since 2007. Of 95
with a “CF suspected” NBS result, 81 were diagnosed with CF (PPV, 0.85). 5
infants with meconium ileus had false negative NBS results with a low IRT-1,
but with no delayed diagnosis. 4 infants had a delayed diagnosis due to a false
negative NBS result (mean age at diagnosis, 10 months). Of these, 3 infants had
IRT-1 values below threshold, and no further testing undertaken. In the 4th infant,
the 4-mutation panel was negative and IRT-1 <99.9th centile. Excluding the infants
with meconium ileus the sensitivity of the protocol is 96%.
The UK protocol was designed to reduce unnecessary stress to families and our data
suggests this has been achieved. Sensitivity is adequate by international standards.
3/4 false negative results were from a low IRT-1. The case missed by the 4 mutation
panel raises concerns about whether the beneﬁts of limiting the initial panel are
outweighed by a reduction in sensitivity.
WS10.2 Complete sequencing of 2,000 cystic ﬁbrosis and
CFTR-related disease high risk alleles
J. Brock1, S. Tobi1, M.J. Schwarz1. 1St Mary’s Hospital, Genetic Medicine,
Manchester, United Kingdom
Since 2007, we have fully sequenced over 2,000 CF and CFTR-Related Disease alle-
les. We have employed fully automated bi-directional ﬂuorescent Sanger sequencing
on samples referred mainly as DNA samples from other regional laboratories. MLPA
(MRC Holland) has also been employed to detect larger deletions or duplications.
Although most referrals were seeking a diagnosis of cystic ﬁbrosis, a growing
number have been for CFTR-Related Diseases, including bronchiectasis, CBAVD
and pancreatitis. Samples from other laboratories had either one or no mutations
already identiﬁed (80% and 20% respectively). Mutations were identiﬁed in 61% of
alleles overall, comprising 175 different CF mutations, of which 25 were previously
undescribed. Twenty-eight cases were found to have large deletions (13 different
mutations in 25 alleles) or duplications (2 in 3 alleles). We have also identiﬁed
a large number of variants of uncertain clinical signiﬁcance, especially in the
CFTR-RD cohort. Patients originating from the Indian Subcontinent demonstrate a
high degree of consanguinity and subsequent homozygosity for rare mutations not
typically seen in the UK native population.
Complete sequencing and MLPA analysis of high risk CF alleles shows up
many different types of mutations, including larger deletions and duplications,
and variations of uncertain clinical signiﬁcance. With the increasing number of
referrals for CFTR-RD, the assessment of novel sequence changes is becoming
more important. A number of cases remain with a strong clinical suspicion, but
without two convincing mutations; in such cases, mRNA analysis is indicated,
which may reveal the presence of deep intron mutations.
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Objectives: Recent technological advances in the next-generation sequencing
(NGS) offer the possibility of re-sequencing analysis of DNA from CF patients in
which only one mutation has been detected. Using two different strategies for whole
CFTR gene (253 kb) sequencing, we report our ﬁrst ﬁndings in underexplored CFTR
gene regions (5′ and 3′ uncoding regions and deep intronic regions) not routinely
analyzed by current scanning methods (mutation detection rate: 95 to 99%).
Methods: Using GS Junior platform (Roche, 70 Mb per run), the two strategies
evaluated consist in a targeted sequencing capture (SeqCap EZ Choice Library
System, NimbleGen) and a pre-ampliﬁcation system by Long Range.
Results: On average 110 sequences variations were detected per DNA. Using ex-
clusion ﬁlters (heterozygosity, SNPs included in databases), we selected 4 variations
per DNA in the large deep intronic sequences. After in silico analysis, two mutations
identiﬁed in two different patients were studied by functional in vitro approaches
(minigene assay) that led to identify new aberrant splicing events.
Conclusion: Identiﬁcation and characterization of mutations in previously unex-
plored regions is a real advance in CF diagnosis and has implication in genetic
counseling for patients and families. Moreover, determination of new mutations of-
fers a highlight for molecular mechanisms that govern transcription and maturation
of the CFTR gene expression.
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WS10.4 A new molecular strategy using CFTR2 data for improving
IRT/DNA screening
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Objectives: Newborn screening (NBS) for CF is ongoing throughout the USA,
and most states analyze 23−40 CFTR mutations when IRT levels are high (2-tier
IRT/DNA algorithm). Infants with 1 mutation are usually referred for sweat testing
but ~90% have normal chloride levels and thus are false positive screens. To improve
NBS, we are evaluating expanded DNA analyses after a single mutation is detected
using a 3rd tier panel of the 157 mutations identiﬁed in the CFTR2 project.
Methods: MiSeqDx™ Cystic Fibrosis Solution, a genotyping-by-sequencing next
generation assay, is being used to detect 157 CFTR mutations that are CF-causing
alleles. Initially, for method validation, specimens from 45 Wisconsin newborns
were evaluated with 2 known CFTR mutations. Mutations identiﬁed by MiSeqDx™
are conﬁrmed by Sanger sequencing.
Conclusion: Validating MiSeqDx™ Cystic Fibrosis Solution for its analytic sen-
sitivity and speciﬁcity using DNA isolated from NBS dried blood specimens,
we found 100% concordance in detecting 90 CFTR alleles. Our experience thus
far demonstrates the feasibility of using next generation sequencing in a public
health laboratory, and establishes the foundation for the further study of a 3-tier
IRT/DNA/DNA screening protocol in reducing false positive results caused by CF
heterozygote carrier infants. In April, we plan on extending the study to states
included in the newly established Great Lakes Consortium (IL, IN, MI, MN, and
WI) which collectively screen more than 500,000 newborns annually. If this 3-tier
method is validated and cost effective, we envision that only newborns with 2
CF-causing mutations might be reported as positive.
